Medivation shares are down and out after its Alzheimer’s drug Dimebon bombed in its first big trial. But the drug may not be completely dead yet, says University of Southern California Alzheimer’s expert Lon Schneider.
Schneider, who generally has been skeptical of Dimebon (see this post), does point to one small ray of hope for Medivation and [...]
great news thought i would never see this.